The consensus price target for Emergent BioSolutions has shifted from US$15 to US$12, with the modeled fair value sitting at US$12 per share. Analysts link this move to reduced earnings expectations ...
Detailed price information for Emergent Biosolutions (EBS-N) from The Globe and Mail including charting and trades.
23h
Emergent BioSolutions Inc (EBS) Q1 2026 Earnings Call Highlights: Strong Revenue and Strategic ...
Emergent BioSolutions Inc (EBS) surpasses revenue expectations and strengthens financial position, while navigating pricing pressures and geopolitical risks.
Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS, SAB BIO) to support the process ...
The Korea Communications Commission (now Korea Media and Communications Commission) has confirmed a lower court’s ruling that its appointment of Shin Dong-ho as president of the Korean Educational ...
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company has closed on a new credit facility agreement with OrbiMed for a new $150 million term loan. The proceeds from the new Term Loan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results